As CND Life Sciences continues to experience growth, launch new diagnostic tests, and expand its impact in the neurodegenerative disease space, the company can’t help but be future-focused. And one way CND invests in the future is by growing talent through an internship program that offers invaluable work experience to its participants.
The mission of the clinical laboratory at CND Life Sciences—to provide timely and accurate test results that aid in the diagnosis and treatment of patients—may not seem different from that of other
labs, but behind this mission you’ll find a unique working environment where the quality of personal interactions and the culture are as important as the quality of the test results.
Be sure to stop by CND Life Sciences’ booth at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, September 21-24 in Nashville, TN. Learn about the complexities of diagnosing autonomic disorders and small fiber neuropathies and how CND’s Syn-One Test® and Small-Fiber Dx™ can help.
Helping clinicians care for patients and putting patients first are core values at CND Life Sciences, and they require going well beyond offering innovative diagnostic tools such as the Syn-One Test®.
CND Life Sciences’ senior scientific advisors Dr. Christopher Gibbons and Dr. Roy Freeman and two members of CND’s scientific team, Todd Levine, MD, and Bailey Bellaire, presented the results of their study titled “Cutaneous Alpha-Synuclein Detection in Patients with Suspected Synucleinopathies” at the Pan American Parkinson’s Disease and Movement Disorders Congress last month in Miami.
Kendall Swanson started at CND Life Sciences as an intern in the summer before her senior year of college. She was studying psychology, and marketing wasn’t an obvious next step for her. However, CND
was introducing its flagship product to the market during a global pandemic and was looking for good talent to make an instant impact.
Drs. Pravin Khemani and Michael Elliot from Swedish Neuroscience Institute in Seattle, Washington, published a case study last month in Parkinsonism and Related Disorders that highlights the role of the Syn-One Test in distinguishing overlapping clinical phenotypes of synucleinopathies from non-synucleinopathies.
The methodology behind the Synuclein-One Study, the largest study to date of cutaneous phosphorylated alpha-synuclein detection, was published this month in Biomarkers in Medicine by CND Life Sciences’ senior scientific advisors Dr. Christopher Gibbons and Dr. Roy Freeman and members of CND’s scientific team, Todd Levine, MD and Bailey Bellaire.
CND Life Sciences is pleased to announce the next webinar in our Tuesday Night Talks series. Todd Levine, MD, CND’s Co-Founder and Chief Medical Officer
welcomes special guest Stuart H. Isaacson, MD, FAAN, Director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, FL to discuss the role and importance of alpha-synuclein as a key